In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

映恩生物招股书数据显示，自2022年以来，全球ADC行业成交量已创下历史新高，跨国公司已成交合共逾20笔许可交易，交易总价值超过600亿美元。中国的生物制药公司已成为重要力量。自2022年以来，逾20项ADC 资产来自于中国公司的授权或被收购，总交易价值超过350亿美元。

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

SHANGHAI (Reuters) - AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

Daiichi Sankyo Company is making significant strides in the pharmaceutical industry, evidenced by its financial growth and strategic collaborations, such as with Merck on MK-6070. The company is set ...

The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...